Clinical TrialsSearch results
Number of results: 778
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- JCOG1914: A clinical trial for elderly patients with unresectable locally advanced non-small cell lung cancer
- Unresectable locally advanced non-small cell lung cancer.
- TAKAHASHI Toshiaki
- 2020-12-04
Other
- A Phase Ib/II study of regorafenib and nivolumab plus chemotherapy in patients with unresectable advanced/recurrent gastric/gastroesophageal junction/esophageal adenocarcinoma
- unresectable advanced/recurrent gastric/gastroesophageal junction/esophageal adenocarcinoma
- Kawazoe Akihito
- 2022-05-25
Other
- Phase2/3 Study of OTS102 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer(PEGASUS-PC Study)
- Unresectable Advanced and Recurrent Pancreatic Cancer
- OncoTherapy Science, Inc.
- 2009-01-27
Other
- Early Phase II clinical trial of PC-SOD -Study of the efficacy and safety of PC-SOD in patients with ulcerative colitis-
- Ulcerative colitis(UC-DAI:more than 4)
- LTT Bio-Pharma Co.,Ltd.
- 2007-06-27
Other
- Establishment of surveillance system for the longstanding ulcerative colitis patients Comparative study of efficacy for the targeted biopsy and the step biopsy
- Ulcerative colitis
- Teikyo University School of Medicine
- 2009-01-05
Other
- Clinical study of combinational therapy of AD-4833 with metformin -Phase III double-blind comparative study-
- Type2 Diabetes
- Takeda Pharmaceutical Company Limited
- 2008-04-04
Recruiting
- Online Diabetes Care Using FreeStyle Libre2 CGM in Japan
- Type 2 diabetes without insulin treatment
- Ono Hiraku
- 2024-06-28
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Metformin
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Sulfonylurea
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Thiazolidine
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01